3-amino-2,6-dihydroxybenzamide | 117885-88-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-amino-2,6-dihydroxybenzamide
• 英文别名: 3-amino-2,6-dihydroxy-benzoic acid amide；3-Amino-2,6-dihydroxy-benzoesaeure-amid
• CAS: 117885-88-8
• 化学式: C₇H₈N₂O₃
• 分子量: 168.152
• InChiKey: BRKPZOXFQIITFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  110
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-amino-2,6-dihydroxybenzamide 在 palladium on activated charcoal 、 水 作用下， 生成 3-amino-2,6-dioxo-cyclohexanecarboxylic acid amide
  参考文献：
  名称：

  Tomino, Chemical and pharmaceutical bulletin, 1958, vol. 6, p. 648,652

  摘要：

  DOI：
• 作为产物：
  描述：

  2,6-dihydroxy-3-nitrobenzamide 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 18.0h， 以80%的产率得到3-amino-2,6-dihydroxybenzamide
  参考文献：
  名称：

  Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent

  摘要：

  In this study a novel bone-targeting agent containing elements of the tricarbonylmethane system of ring A of tetracycline was developed and was shown to bind to the mineral constituent of bone, hydroxyapatite. Conjugation of this bone-targeting agent to estradiol resulted in a bone-targeted estrogen (BTE2-A1) with an enhanced ability to bind to hydroxyapatite. In an ovariectomized rat model of osteoporosis a partial separation of the skeletal effects of estradiol from the uterine effects was observed following subcutaneous administration of BTE2-A1. This novel bone-targeting estradiol delivery system has the potential to improve the safety pro. le of estradiol in the treatment of osteoporosis. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.051

文献信息

• Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders
  申请人：Pierce M. William

  公开号：US20050143366A1

  公开（公告）日：2005-06-30

  The present invention relates to compounds of the formula or pharmaceutically acceptable salts thereof useful for the prophylaxis and treatment of degenerative bone disorders and for the acceleration of bone healing.

  本发明涉及以下式的化合物或其药用可接受盐，用于预防和治疗退行性骨疾病以及促进骨愈合。
• Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent
  作者：Jason R. Neale、Natali B. Richter、Kevyn E. Merten、K. Grant Taylor、Sujan Singh、Leonard C. Waite、Nicole K. Emery、Ned B. Smith、Jian Cai、William M. Pierce

  DOI：10.1016/j.bmcl.2008.12.051

  日期：2009.2

  In this study a novel bone-targeting agent containing elements of the tricarbonylmethane system of ring A of tetracycline was developed and was shown to bind to the mineral constituent of bone, hydroxyapatite. Conjugation of this bone-targeting agent to estradiol resulted in a bone-targeted estrogen (BTE2-A1) with an enhanced ability to bind to hydroxyapatite. In an ovariectomized rat model of osteoporosis a partial separation of the skeletal effects of estradiol from the uterine effects was observed following subcutaneous administration of BTE2-A1. This novel bone-targeting estradiol delivery system has the potential to improve the safety pro. le of estradiol in the treatment of osteoporosis. (c) 2008 Elsevier Ltd. All rights reserved.
• Tomino, Chemical and pharmaceutical bulletin, 1958, vol. 6, p. 648,652
  作者：Tomino

  DOI：——

  日期：——